Alector, Inc.: FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) : vimarsana.com

Alector, Inc.: FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Alector, Inc.: FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Related Keywords

South San Francisco , California , United States , Spain , Germany , France , Italy , America , Arnon Rosenthal , Stefan Klotter , Dan Budwick , Laura Perry , Katie Hogan , Alector Inc , Nasdaq , Exchange Commission , Drug Administration , European Union , Association For Frontotemporal Degeneration , Breakthrough Therapy Designation , Chief Executive Officer , Therapy Designation , Orphan Drug Designation , Breakthrough Therapy , Fast Track , Frontotemporal Dementia , Drug Administration Approved , Private Securities Litigation Reform Act , Annual Reports , Quarterly Reports , Frontotemporal Degeneration , Die Performance Strategie , Assets Sie ,